Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
3상
완료
NCT04662710
| 대상 질환 | Advanced/Metastatic Gastroesophageal Adenocarcinoma |
|---|
| 임상 단계 | 3상 |
|---|
| 스폰서 | Merck Sharp & Dohme LLC |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 895 명 |
|---|
| 중재(약물) | Pembrolizumab, Lenvatinib, Oxaliplatin, Capecitabine, Leucovorin (or Levoleucovorin) |
|---|
| 시작일 | 2020년 12월 30일 |
|---|
| 완료일 | 2024년 10월 29일 |
|---|
| 결과 공개일 | 2025년 11월 28일 |
|---|
요약
The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared with chemotherapy alone in participants with advanced/metastatic gastroesophageal cancer. The primary study hypotheses are that lenvatinib plus pembrolizumab plus chemotherapy is superior to chemotherapy alone for both overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR), in participants with programmed cell death-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 and in all participants.
Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)
Up to ~21 days · Participants
| Part 1 : Lenvatinib + Pembrolizumab + Chemotherapy | 2 Participants |
|---|
Part 1: Number of Participants With Adverse Events (AEs)
Up to ~44 months · Participants
| Safety Run-In: Lenvatinib + Pembrolizumab + Chemotherapy | 15 Participants |
|---|
Part 1: Number of Participants Who Discontinued Study Treatment Due to an AE
Up to ~29 months · Participants
| Safety Run-In: Lenvatinib + Pembrolizumab + Chemotherapy | 5 Participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.